FDA Approves Roche’s Wilserdly With Everolimus, Cuts Breast Cancer Progression Risk 62%
Key Facts
The U.S. Food and Drug Administration on November 16, 2026, approved giredestrant, marketed by Genentech as Wilserdly, in combination with everolimus to treat adults with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation. The decision requires that the disease have been treated previously under conditions set by the agency. The approval gives the combination to a specific group of patients whose tumors carry this mutation, rather than extending it to all breast cancer cases. The FDA also authorized the FoundationOne Liquid CDx test as a companion diagnostic to identify eligible patients. The agency said the approval came four weeks ahead of its target review date.
The efficacy assessment was based on the evERA trial, a randomized, open-label, multicenter study that enrolled 373 adults with advanced estrogen receptor-positive, HER2-negative breast cancer, including 207 patients whose tumors carried ESR1 mutations. In this group, median progression-free survival was 10 months among those who received giredestrant with everolimus, compared with 5.5 months with physician’s choice of endocrine therapy and everolimus. The objective response rate was 27% with the new combination, compared with 14% in the comparator group. Roche said the risk of disease progression or death fell 62% compared with standard hormone therapy with everolimus. It estimated the hazard ratio at 0.38, with a 95% confidence interval from 0.27 to 0.54 and a p-value of less than 0.0001.
In the overall study population, median progression-free survival was 8.8 months with giredestrant and everolimus, compared with 5.5 months with the comparator therapy and everolimus, according to a summary by Dana-Farber. The institute said this represented a 44% reduction in the risk of disease progression or death among all participants. Participants were followed for a median of 18.6 months. Lead investigator Erica Mayer said the approval gives patients a new treatment option that improves disease control, with a regimen taken entirely by mouth. Overall survival data were immature at the time of the progression-free survival analysis, according to the FDA.
The treatment targets a pathway linked to resistance to hormone therapy in some patients. Roche said up to 40% of patients with hormone receptor-positive metastatic breast cancer may develop ESR1 mutations associated with treatment resistance and disease progression. Giredestrant, according to Dana-Farber, works by binding to the estrogen receptor and promoting its degradation, while everolimus targets the mTOR protein, which is associated with cell growth and survival. The recommended dose of giredestrant is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. The institute said about 70% of breast cancer cases are estrogen receptor-positive.
The most common adverse reactions, occurring in at least 20% of patients who received the combination, include stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. The FDA also listed bradycardia and embryo-fetal toxicity among the warnings. These risks underscore the need to weigh the efficacy reported in the trial against the side effects identified in the treatment labeling. In the market, Roche shares, traded under the ticker RHHBY, closed at $60.95 on November 16, the day the approval was announced. Novartis shares, whose Afinitor drug contains the generic ingredient everolimus, closed at $160.20 on the same day.
Roche is awaiting another regulatory step involving giredestrant, as the FDA was reviewing an application to use it as adjuvant treatment after surgery for early breast cancer. The agency set November 30, 2026, as the target date for a decision on that application. The upcoming review links the drug to an earlier stage of the disease, while the approval issued on November 16 is limited to locally advanced or metastatic disease with an ESR1 mutation. Roche said approval of Wilserdly marks the drug’s first approval, and the FDA confirmed the U.S. approval date. The pending decision on adjuvant use therefore remains a separate regulatory milestone from approval of the current combination.